Welcome to our dedicated page for Certara SEC filings (Ticker: CERT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Certara, Inc. (NASDAQ: CERT) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Certara is a biosimulation and model‑informed drug development company whose common stock is registered on The Nasdaq Stock Market LLC under the symbol CERT, as disclosed in its Form 8‑K filings.
Investors can review current reports on Form 8‑K, which Certara uses to announce material events. Recent 8‑K filings include press releases for quarterly financial results, where the company reports revenue from biosimulation software and services, bookings, and updates to its full‑year financial outlook. Other 8‑K filings document corporate developments such as amendments to the company’s credit agreement and leadership changes, including the appointment of a new chief executive officer.
In addition to 8‑K reports, users can expect to find annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available), which typically provide more detailed discussions of Certara’s business, risk factors, and financial statements. Filings related to financing arrangements, such as amendments to term loan facilities, are also included and can offer insight into the company’s capital structure and borrowing costs.
Stock Titan enhances these documents with AI‑powered summaries that explain key sections of lengthy filings, helping readers quickly identify important information without reading every page. Real‑time updates from EDGAR ensure that new Certara filings appear promptly, while dedicated sections surface insider transaction reports on Form 4 and other ownership‑related disclosures when they are filed.
By using this page, investors and researchers can follow Certara’s regulatory reporting history, track material events, and better understand how the company describes its biosimulation software, services, and financial performance in official SEC documents.
The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting 0 shares and 0% beneficial ownership of Certara Inc common stock. The amendment explains that on January 12, 2026 The Vanguard Group, Inc. completed an internal realignment and certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538.
The filing lists 0 shares with 0% voting and dispositive power and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Certara, Inc. reported that director Arjun Bedi acquired 5,547 restricted stock units (RSUs) on February 27, 2026 as a grant under the Certara, Inc. 2020 Incentive Plan. Each RSU represents one share of common stock and will vest on the earlier of the one-year anniversary of the grant date or the company’s next annual meeting.
Certara, Inc. director Arjun Bedi filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as a reporting insider of the company but does not report any specific stock transactions or changes in ownership.
Certara, Inc. presents an annual overview of its biosimulation-focused business, strategy, and risks. The company provides modeling, data, AI and regulatory consulting tools that help biopharmaceutical customers design better trials, support drug approvals and manage regulatory submissions.
Certara’s software and services have been used by more than 2,600 organizations, with over 160,000 licensed users and 20 global drug regulators. Customers include 38 of the top 40 biopharmaceutical companies by R&D spend. As of February 17, 2026, Certara had 159,139,562 common shares outstanding.
The report highlights growing use of model‑informed drug development, expansion into AI-enabled workflows and the 2024 acquisition of Chemaxon to strengthen discovery informatics. It also outlines extensive risk factors, including regulatory shifts, R&D spending pressures, competition, AI-related challenges, FDA operational disruptions and macroeconomic headwinds.
Certara reported solid but mixed fourth quarter and full-year 2025 results and set cautious 2026 guidance. Full-year 2025 revenue was $418.8 million, up 9%, with software revenue up 18% to $183.3 million and services up 3% to $235.6 million. Adjusted EBITDA reached $134.5 million, implying a margin of about 32%, while GAAP net loss narrowed to $1.6 million.
In the fourth quarter, revenue grew 3% to $103.6 million, as software rose 10% to $46.4 million but services slipped 1% to $57.3 million. The company swung to a net loss of $5.9 million from $6.6 million of net income, mainly due to higher operating expenses. Total bookings grew 7% to $155.2 million, with strong 17% growth in services bookings offset by a 6% decline in software bookings.
Certara appointed Jon Resnick as CEO effective January 1, 2026. For 2026, the company guides to revenue growth of 0–4%, adjusted EBITDA margin of 30–32%, and adjusted diluted EPS of $0.44–$0.48 on 160–162 million fully diluted shares. Cash and cash equivalents were $189.4 million at year-end.
Certara, Inc. filed an initial insider ownership report for its Chief Executive Officer and director, Jon Matthew Resnick. This Form 3 identifies Resnick as both a director and the Chief Executive Officer of Certara, Inc. as of 01/01/2026. The filing states in the remarks section that Exhibit 24 – Power of Attorney (POA) is included and that no securities are beneficially owned, meaning Resnick is not reporting any direct or indirect ownership of Certara, Inc. securities at this time. The form is signed by an attorney-in-fact acting on Resnick’s behalf.
Certara, Inc. is making a planned leadership change, appointing Jon Resnick as Chief Executive Officer effective January 1, 2026, succeeding Dr. William F. Feehery, who will step down as CEO and director at the close of December 31, 2025. Resnick will also join the Board as a Class III director with a term running until the 2026 annual stockholder meeting.
Resnick’s employment agreement sets an initial annual base salary of $750,000 and a target bonus equal to 100% of salary. He will receive a $6,500,000 make‑whole restricted stock unit grant vesting over the first two years, a pro‑rata 2025 long‑term incentive award targeted at $4,000,000 and a 2026 long‑term incentive award targeted at $8,000,000, both split between performance‑vesting and time‑vesting equity. If he is terminated without cause or resigns for good reason, he is eligible for cash severance, continued health coverage and accelerated or prorated equity vesting, with enhanced terms if this occurs around a change in control. Dr. Feehery will provide transition consulting services for a $20,000 monthly fee and receive pro‑rata vesting on certain 2025 equity awards.
Certara (CERT) reported an insider buy by its CEO. William F. Feehery, who serves as Chief Executive Officer and Director, purchased 24,096.384 shares of Common Stock on 11/11/2025 at $8.3 per share (transaction code P). Following this transaction, his directly held stake stands at 2,360,769.384 shares.
Certara, Inc. reported continued growth in Q3 2025. Revenue for the quarter reached $104.6 million, up from $94.8 million a year ago, and year‑to‑date revenue rose to $315.2 million from $284.8 million. The company posted quarterly net income of $1.5 million versus a loss last year, and year‑to‑date net income of $4.3 million compared with a prior-year loss. Gross cost trends remained controlled as operating expenses rose modestly alongside higher sales.
Cash generation strengthened and the balance sheet remained liquid. Cash and cash equivalents were $172.7 million as of September 30, 2025. Net cash provided by operating activities was $67.5 million year‑to‑date, more than double the prior year. Term loans stood at $296.3 million, with an effective rate of 7.39% year‑to‑date. The company executed share repurchases of $38.7 million in 2025, increasing treasury stock to 4,477,064 shares. Revenue mix showed software licenses and services both contributing, while deferred revenue was $65.9 million, supporting near‑term visibility. Interest rate risk is hedged with swaps totaling $230.0 million notional maturing in 2029.
Certara, Inc. furnished an 8‑K to announce that it issued a press release with financial results for the three-month period ended September 30, 2025. The press release is attached as Exhibit 99.1.
The information provided under Item 2.02 (Results of Operations and Financial Condition), including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference into other filings. The submission also includes Exhibit 104, the Cover Page Interactive Data File (Inline XBRL).